Adam Krouse, DO
Family Medicine · Edmond, OKNPI 1588919476
Payments from drug & device makers
Across 146 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$456
- Novo Nordisk$191
- Amgen$179
- GSK$167
- Pfizer$166
- Takeda Pharmaceuticals U.S.A., Inc.$130
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,302100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $456 |
| Novo Nordisk | 13 | $191 |
| Amgen(2 entities) | 11 | $179 |
| GSK | 14 | $167 |
| Pfizer | 12 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $130 |
| Corium, LLC | 7 | $122 |
| Amarin Pharma, Inc. | 7 | $97 |
| Genentech USA, Inc. | 5 | $84 |
| AstraZeneca | 6 | $81 |
| Merck | 5 | $77 |
| Eisai Inc. | 5 | $75 |
| Dexcom, Inc. | 4 | $67 |
| Lilly USA, LLC | 3 | $48 |
| Nestle Healthcare Nutrition Inc. | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Hologic Sales And Service, LLC | 2 | $36 |
| Johnson & Johnson | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Dynavax Technologies Corporation | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$2,302 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $89,175 |
| EliquisApixaban | 40 | $57,366 |
| JardianceEmpagliflozin | 19 | $32,530 |
| TrulicityDulaglutide | 26 | $30,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $26,375 |
| JanuviaSitagliptin Phosphate | 18 | $25,488 |
| MyrbetriqMirabegron | 23 | $15,527 |
| FarxigaDapagliflozin Propanediol | 15 | $14,669 |
| MounjaroTirzepatide | 17 | $13,111 |
| XareltoRivaroxaban | 11 | $12,381 |
| Atorvastatin Calcium | 319 | $3,958 |
| Dexlansoprazole DrDexlansoprazole | 15 | $3,534 |
| Omeprazole | 135 | $3,166 |
| Gabapentin | 161 | $3,139 |
| Levothyroxine Sodium | 270 | $3,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $191 | $89,17569 claims |
| PfizerEliquis | $166 | $57,36640 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $48 | $43,38943 claims |
| GSKTrelegy Ellipta | $167 | $26,37525 claims |
| MerckJanuvia | $77 | $25,48818 claims |
| AstraZenecaFarxiga | $81 | $14,66915 claims |
| Johnson & JohnsonXarelto | $29 | $12,38111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Susan DimickEdmond$256K
- Charles WoodwardEdmond$15K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.